A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-in
about
Direct-acting antivirals for chronic hepatitis C.Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection.Preclinical characterization of GSK2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5APharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845 (GSK2336805) in subjects with hepatic impairment.Direct-acting antivirals for chronic hepatitis C
P2860
A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-in
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A double-blind, randomized, pl ...... epatitis C virus genotype 1-in
@en
type
label
A double-blind, randomized, pl ...... epatitis C virus genotype 1-in
@en
prefLabel
A double-blind, randomized, pl ...... epatitis C virus genotype 1-in
@en
P2093
P2860
P356
P1433
P1476
A double-blind, randomized, pl ...... epatitis C virus genotype 1-in
@en
P2093
Amy Cutrell
Cindy Elko-Simms
Jill Walker
Kimberly Adkison
Maribel Rodriguez-Torres
Robert Hamatake
Stephen Gardner
P2860
P304
P356
10.1111/LIV.12334
P577
2013-10-16T00:00:00Z